DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20201743

A prospective comparative study to evaluate the efficacy and safety of olopatadine eye drops and bepotastine eye drops in subjects of vernal kerato conjunctivitis

Amatur R. Malahat, Sudhakar Kodudula, Vijaya L. Gali

Abstract


Background: Vernal keratoconjunctivitis (VKC) is an allergic eye disease that especially affects young boys. Both olopatadine and bepotestine are dual acting drugs that provide rapid symptomatic relief coupled with the long-term disease-modifying benefit. The present study is conducted to compare the efficacy and safety of olopatadine eye drops and bepotastine eye drops in patients of vernal keratoconjunctivitis.

Methods: A prospective, randomized, parallel-group, comparative study is conducted over a period of 4 weeks on paediatric patients with VKC. 50 patients are recruited and randomized into two treatment groups. They received the assigned drugs for 4 weeks and are called for follow up at the end of 1st week, 4th week and 12th week. At each follow-up, patients are examined and the clinical parameters are graded.

Results: This study shows that both olopatadine and bepotastine are equally efficacious. Bepotastine provided quicker relief to symptoms of watering, ocular discomfort and conjunctival hyperaemia. Number of responders are also more in the bepotastine group. Absolute eosinophilic count improved with both the drugs but there is no statistically significant difference between them. Both drugs showed good safety profile. However, 24% patients reported aversion to bitter taste with bepotastine. There is no treatment related severe adverse effects in both the groups.

Conclusions: Both olopatadine and bepotastine are effective in treating vernal keratoconjunctivitis. However, bepotastine performed better in reducing tearing, ocular discomfort and conjunctival hyperaemia.


Keywords


Bepotastine, Efficacy, Olopatadine, Safety, Vernal keratoconjunctivitis

Full Text:

PDF

References


Abelson MB, Shetty S, Korchak M, Butrus SI, Smith LM. Advances in pharmacotherapy for allergic conjunctivitis. Expert Opin Pharmacother. 2015;16(8):1219-31.

Akil H, Celik F, Ulas F, Kara IS. Dry eye syndrome and allergic conjunctivitis in the pediatric population. Middle East Afr J Ophthalmol. 2015;22(4):467-71.

Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832-6.

Rosa ML, Lionetti E, Reibaldi M, Russo A, Longo A, Leonardi S, et al. Allergic conjunctivitis: a comprehensive review of the literature. Ital J Pediatr. 2013;39:18.

Alemayehu AM, Yibekal BT, Fekadu SA. Prevalence of Vernal Keratoconjunctivitis and its associated factors among children in Gambella town, southwest Ethiopia, June 2018 PLoS One. 2019;14(4): e0215528.

Kumar S. Vernal keratoconjunctivitis: a major review. Acta Ophthalmol. 2009;87:133-47.

Ackerman S, Smith LM, Gomes PJ. Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management. Ther Adv Chronic Dis. 2016;7(1):52-67.

Mishra GP, Tamboli V, Jawla J, Mitra AK. Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis. Recent Pat Inflamm Allergy Drug Discov. 2011;5:26-36.

Uchio E. Treatment of allergic conjunctivitis with Olopatadine hydrochloride eye drops Clin Ophthalmol. 2008;2(3):525-31.

Bergmann MT, Williams JI, Gomes PJ. Treatment of allergic conjunctivitis with Bepotastine besilate ophthalmic solution 1.5%. Clin Ophthalmol. 2014;8:1495-505.

Zaki SA. Adverse drug reaction and causality assessment scales Lung India. 2011 Apr-;28(2):152-3.

Wani RT. Socioeconomic status scales modified Kuppuswamy and Udai Pareekh’s scale updated for 2019. J Family Med Prim Care. 2019;8(6):1846-9.

Leonardi A, Bogacka E, Fauquert JL, Kowalski ML, Groblewska A, Jedrzejczak‐Czechowicz M, et al. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. Allergy. 2012;67(11):1327-37.

Saboo US, Jain M, Reddy JC, Sangwan VS. Demographic and clinical profile of Vernal Keratoconjunctivitis at a tertiary eye care center in India. Indian J Ophthalmol. 2013;61(9):486-9.

De Smedt S, Nkurikiye J, Fonteyne Y, Hogewoning A, Esbroeck MV, De Bacquer D, et al. Am J Trop Med Hyg. 2011;85(4):711-7.

McCabe CF, McCabe SE. Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference. Clini Ophthalmol (Auckland, NZ). 2012;6:1731-8.